TEL AVIV, March 16 Israel's MedyMatch Technology
said on Thursday IBM Watson Health would integrate
MedyMatch's technology into its offerings to imaging experts in
hospitals to help doctors identify intracranial bleeding from
head trauma and stroke.
Initially, IBM Watson Health will distribute the MedyMatch
brain bleed detection application globally through its sales
channels. Later, IBM Watson Health and MedyMatch will develop
interoperability between MedyMatch's application and IBM Watson
Health Imaging's offerings.
The initial deal is a five-year license agreement that will
result in several millions of dollars in annual recurring
licensing fees to MedyMatch, the company said.
MedyMatch is conducting a clinical trial for its
intracranial bleed assessment application and is working towards
approval by the U.S. Food and Drug Administration.
(Reporting by Tova Cohen)